0.62
-0.0177(-2.80%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.63 |
| Day High | 0.64 |
| Day Low | 0.61 |
| 52-Week High | 2.24 |
| 52-Week Low | 0.59 |
| Volume | 355,120 |
| Average Volume | 456,621 |
| Market Cap | 13.13M |
| PE | -0.63 |
| EPS | -0.98 |
| Moving Average 50 Days | 0.76 |
| Moving Average 200 Days | 1.17 |
| Change | -0.02 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $8.3 as of December 07, 2025 at a share price of $0.615. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $17.83 as of December 07, 2025 at a share price of $0.615.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
GlobeNewswire Inc.
Dec 03, 2025 2:15 PM GMT
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Long
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
GlobeNewswire Inc.
Dec 02, 2025 2:15 PM GMT
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardio
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
GlobeNewswire Inc.
Dec 01, 2025 5:00 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel